News | Implantable Cardiac Monitor (ICM) | July 11, 2024

Amvia Sky Launched in Canada, the World’s First Pacemaker Approved for LBBAP

First implant of Amvia Sky in Canada performed at the Centre Hospitalier de l'Université de Montréal

First implant of Amvia Sky in Canada performed at the Centre Hospitalier de l'Université de Montréal

July 11, 2024 — Dr. Fadi Mansour performed the first Canadian implant of BIOTRONIK’s newest pacemaker and CRT-P generation earlier this year at the Centre Hospitalier de l'Université de Montréal. The patient received an Amvia Sky HF-T QP triple chamber pacemaker device. The first implant follows the full market release of BIOTRONIK’s newest family of pacemaker and CRT-P devices, featuring patient-centric technologies for better patient care and simplified workflows.

“The Amvia Sky HF-T QP offers a significant number of advanced features, making it the most complete CRT-P on the market including streamlined care pathways,” commented Dr. Mansour after the procedure.

The Amvia Sky system offers the following new features:

  • Industry-leading choice with 20 left ventricular (LV) pacing polarities, automatically tested in less than 2.5 minutes.
  • CRT AutoAdapt which automatically adjusts to changes in the patient’s condition for a more personalized response.
  • Enhanced Closed Loop Stimulation (CLS) rate adaptation technology.
  • Atrial arrhythmia management tools, including atrial antitachycardia pacing (ATP).
  • Streamlined Care Pathways.
  • Next-generation MRI access with MRI Guard 24/7.

“BIOTRONIK is dedicated to continually improving our technologies, and the Amvia Sky family is a great example of this commitment,” said Angela McGonigle, Country Director BIOTRONIK Canada. “Our latest family of pacemaker and CRT-P devices offers advanced features for optimized therapy and improved workflow simplification for Allied Health Professionals.”

For more information: www.biotronik.com


Related Content

Feature | Heart Failure | Kyle Hardner

Editor's Note: This is Part Three of a three-part series highlighting several of the presentations from the American ...

Home May 13, 2026
Home
News | Heart Failure

May 10, 2026 — Results from the first randomized trial evaluating microRNA inhibition in heart failure were presented ...

Home May 11, 2026
Home
Feature | Heart Failure | Kyle Hardner

Could a link between the heart, brain and immune system help reduce the occurrence of heart attacks and lessen the ...

Home May 04, 2026
Home
News | Heart Failure

April 21, 2026 — Nuwellis, Inc. has announced a software update to its Aquadex SmartFlow ultrafiltration platform. The ...

Home April 23, 2026
Home
News | Heart Failure

March 28, 2026 — Amgen announced today that Repatha (evolocumab), when added to statins or other low-density lipoprotein ...

Home April 06, 2026
Home
News | Heart Failure

March 24, 2026 — New research shows that small improvements to sleep, diet quality and physical activity, made in ...

Home March 25, 2026
Home
News | Heart Failure

March 16, 2026 — Cytokinetics has announced four presentations related to Myqorzo (aficamten) at the American College of ...

Home March 16, 2026
Home
Feature | Heart Failure | Rohit Sood, MD, PhD

Cardiovascular disease (CVD) is a serious global health burden that encompasses a broad group of diseases that affect ...

Home February 12, 2026
Home
News | Heart Failure

Feb. 3, 2026 — Bristol Myers Squibb has launched "Change the Target. Change What’s Possible," an educational campaign ...

Home February 03, 2026
Home
News | Heart Failure

Jan. 27, 2026 — A new national study reveals a stark disconnect between Americans’ desire for preventive cardiac ...

Home January 27, 2026
Home
Subscribe Now